<DOC>
	<DOCNO>NCT00003557</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness dolastatin 10 treat patient metastatic recurrent liver , bile duct , gallbladder cancer .</brief_summary>
	<brief_title>Dolastatin 10 Treating Patients With Metastatic Or Recurrent Liver , Bile Duct , Gallbladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate , time progression , survival patient previously untreated advanced hepatobiliary cancer treat dolastatin 10 . II . Determine toxicity regimen patient population . OUTLINE : This open label , multicenter study . Patients receive dolastatin 10 IV bolus every 3 week . Treatment continue minimum 2 course absence unacceptable toxicity disease progression . Patients follow death . PROJECTED ACCRUAL : A total 14-35 evaluable patient accrue study within 9 month .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Dolastatin 10</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic , locally advanced , recurrent cancer liver ( hepatoma ) , bile duct , gallbladder ( cholangiocarcinoma ) Bidimensionally measurable disease The following consider measurable lesion : Lesions see colonoscopic examination barium study Bone metastases CNS lesion CEA , CA199 , AFP level Ascites No CNS disease No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : CALGB 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 OR Platelet count least 75,000/mm3 patient clinically document sequestration hemodilution unrelated primary bone marrow insufficiency Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant underlie medical psychiatric illness No active infection No malignancy within past 5 year except curatively treat nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy advance metastatic hepatobiliary cancer No concurrent chemotherapy No concurrent investigational antineoplastic drug Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy site measurable disease At least 6 week since prior radiotherapy recover No concurrent radiotherapy lesion Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>cholangiocarcinoma gallbladder</keyword>
</DOC>